NEW YORK ( TheStreet) -- Enzon Pharmaceuticals (Nasdaq: ENZN) hit a new 52-week low Thursday as it is currently trading at $8.86, below its previous 52-week low of $9.09 with 130,992 shares traded as of 11 a.m. ET. Average volume has been 392,200 shares over the past 30 days.

Enzon has a market cap of $499.8 million and is part of the health care sector and drugs industry. Shares are down 23% year to date as of the close of trading on Wednesday.

Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs.
  • Practice your ENZN trading strategies and win cash in our stock game.

TheStreet Ratings rates Enzon as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full Enzon Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.